This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Istituto Nazionale Delle Malattie Infettive “Lazzaro Spallanzani” Irccs. Active years: 2010.
Company Filing History:
Years Active: 2010
Title: **Fabrizio Poccia: A Pioneer in Tuberculosis Diagnostics**
Introduction
Fabrizio Poccia, an accomplished inventor based in Rome, Italy, has made significant contributions to the field of medical diagnostics. With a focus on tuberculosis, one of the world's most pressing public health concerns, his work is vital for improving diagnosis and monitoring of this disease.
Latest Patents
Fabrizio Poccia holds a patent for an innovative method titled "Immune diagnostic assay to diagnose and monitor tuberculosis infection." This invention provides a comprehensive approach to identifying and tracking various presentations of tuberculosis, including active disease, latent infection, and recent infections. The rapid immune assay he developed evaluates the frequency of Interferon (IFN) gamma-producing antigen-specific T lymphocytes in response to selected peptide sequences known for their immunogenicity. Additionally, the invention encompasses immunogenic and vaccine compositions derived from these specific peptide sequences.
Career Highlights
Fabrizio Poccia works at the Istituto Nazionale Delle Malattie Infettive “Lazzaro Spallanzani” IRCCS, where he contributes to groundbreaking research aimed at combatting infectious diseases. His dedication to advancing medical science has led to impactful innovations that enhance our understanding and management of tuberculosis.
Collaborations
Throughout his career, Poccia has collaborated with esteemed colleagues including Delia Goletti and Donatella Vincenti. Together, they leverage their expertise to push the boundaries of infectious disease research, combining their efforts to enhance the diagnostic capabilities related to tuberculosis and other infectious conditions.
Conclusion
Fabrizio Poccia exemplifies the essence of innovation in the field of medical diagnostics. His patent on immune diagnostic assays represents a significant advancement in tuberculosis management, reflecting his commitment to improving public health through scientific inquiry and collaboration.